Skip to main content
Premium Trial:

Request an Annual Quote

The Joy of a New Toy

Cancer Research UK's James Hadfield has been putting his lab's new HiSeq through its paces. The machine passed its validation run "with flying colours," Hadfield says on the SeqAnswers message board. "The validation run was a pair of PE flowcells with PhiX at 36bp read lengths. We obtained 51.5 and 56.0Gb of data from the flowcells which extrapolates to just over 300Gb from the run at PE100bp," he says, adding that he was so happy to get such a boost over 200Gb that he's pretty much sold on the HiSeq. The speed of data generation combined with the machine's ability to do two flowcells per instrument is going to make the HiSeq "indispensable," Hadfield says. With so much data being generated, however, collaboration with other labs is going to be key in analyzing it all, he adds.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.